Zevra Therapeutics Inc

ZVRA is in Stage 3 distribution following a decisive Support Failure, with medium-term bias firmly bearish. Short-term price trades below declining 9EMA and 20EMA, rejecting rallies at EMA resistance. Execution is Sell Now into the EMA resistance zone, while key risks include potential support at the rising 50SMA and short-term relief bounces.

• ↑Q1 net revenue reached $36.2M (+78% YoY), signaling robust MyPlypha demand.
• ↑Patent protection extended through November 2041, reducing exclusivity risk and raising price targets to $29.
• ↓European approval process remains uncertain, with label and pricing outcomes undetermined.